No evidence for carcinogenicity in exposed humans was found in the available literature.
Animal studies provide sufficient evidence that mirex and its metabolite (chlordecone) are carcinogenic after oral exposure. Carcinogenic potential has not been tested by the inhalation or dermal routes. Effects after inhalation exposure are unlikely because of low volatility. Evidence suggests that chlordecone and mirex are epigenetic carcinogens, and a twostage initiationpromotion study in rats provides strong evidence for liver tumour promotion activity of chlordecone.
The Department of Health and Human Services (DHHS) determined that mirex may reasonable be anticipated to be a human carcinogen. The International Agency for Research on Cancer (IARC) determined that mirex may possibly cause cancer in humans. US EPA has not listed mirex on its Carcinogens List.